Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

This study found that all lesions in mice treated with a new topical formulation, WR 279,396, healed completely without relapse, outperforming other formulations and showing no toxicity.

This review discusses potential agents, including acetyl-L-carnitine and vitamins, for repurposing in managing chemotherapy-induced peripheral neuropathy and reports no clinical results; the authors emphasize the need for further research.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.

This study presents four cases of delusions of parasitosis and introduces escitalopram as a potential therapy, highlighting its fewer side effects compared to the commonly used pimozide.

Teriflunomide can cause hair thinning.

This review found that Seenthil Chooranam, a traditional Siddha formulation, has potential therapeutic benefits for various diseases due to its pharmacological properties and bioactive compounds, though further research is needed to confirm its safety and clinical effectiveness.

This study, involving patients with early rheumatoid arthritis, found that treatment regimens combining methotrexate and glucocorticoids, with or without initial high-dose methylprednisolone, showed higher remission rates over one year compared to methotrexate or leflunomide alone, and all regimens were generally well-tolerated.

In this study, the researchers reported that the safety profile was similar across all DMARD treatment regimens for early rheumatoid arthritis, but the most severe side effects occurred in the leflunomide group.